Read by QxMD icon Read

Tcga bladder

Gui-Min Wen, Fei-Fei Mou, Wei Hou, Dan Wang, Pu Xia
CD133 is a wildly used cancer stem cell marker. The purpose of this study was to explore the significance of CD133 mRNA in human cancers mainly based on The Cancer Genome Atlas (TCGA) database. Bioinformatic analyses were done by using public repositories, including BioGPS, SAGE Genie tools, Oncomine analysis, Regulome Explorer, COSMIC analysis, and Kaplan-Meier Plotter. The main findings in this study were: 1) High CD133 mRNA was correlated with a benign survival rate of gastric cancer and lung cancer; 2) Transmembrane protein 125 (TMEM125) in bladder urothelial carcinoma and intercellular adhesion molecule 2 (ICAM2) in ovarian serous cystadenocarcinoma were closely related to CD133 expression; 3) The location and the topological structure of CD133 protein were not determined by its transcript variant in cancer cells; 4) CD38 and CD200 may be used as novel surface markers for solid cancers...
November 14, 2018: Stem Cell Reviews
João Lobo, Daniela Barros-Silva, Rui Henrique, Carmen Jerónimo
Epitranscriptomics has gained ground in recent years, especially after the advent of techniques for accurately studying these mechanisms. Among all modifications occurring in RNA molecules, N6-methyladenosine (m⁶A) is the most frequent, especially among mRNAs. m⁶A has been demonstrated to play important roles in many physiological processes and several disease states, including various cancer models (from solid to liquid tumors). Tumor cells' epitranscriptome is indeed disrupted in a way to promote cancer-prone features, by means of up/downregulating m⁶A-related players: the so-called writers, readers and erasers...
November 13, 2018: Genes
Da-Wei Tian, Zhou-Liang Wu, Li-Ming Jiang, Jie Gao, Chang-Li Wu, Hai-Long Hu
Neddylation has been researched in many different human carcinomas. However, the roles of neural precursor cell expressed, developmentally down-regulated 8 (NEDD8) in bladder cancer were still unknown. Our study was the first study which systematically investigated the possible functions of NEDD8 in bladder cancer (BC) progression. We performed immunohistochemistry to explore the associations between the expression of NEDD8 in tumor tissues and clinical outcomes of patients. RT-qPCR and western blot were used to detect the expressional levels of genes...
November 8, 2018: Cancer Science
Jingfei Teng, Xing Ai, Zhuomin Jia, Kai Wang, Yawei Guan, Yanjie Guo
Accumulative reports have documented the critical functions of long non-coding RNAs (lncRNAs) in the progression of malignant tumors, including bladder cancer (BCa). LncRNA ARAP1-AS1 was chosen to be the object of this study due to it was significantly upregulated in the BCa samples of TCGA database. qRT-PCR further validated the dysregulation of ARAP1-AS1 in 88 pairs of BCa tissues and six BCa cells. Kaplan Meier analysis was utilized to analyze the prognostic value of ARAP1-AS1 for patients with BCa. To evaluate the oncogenic property of ARAP1-AS1 in bladder cancer, loss-of-function assays were conducted in two BCa cells in which ARAP1-AS1 was expressed highest...
November 7, 2018: Cancer Biology & Therapy
Margaritis Avgeris, Anastasia Tsilimantou, Panagiotis K Levis, Theodoros Tokas, Diamantis C Sideris, Konstantinos Stravodimos, Alexandros Ardavanis, Andreas Scorilas
BACKGROUND: Bladder cancer (BlCa) heterogeneity and the lack of personalised prognosis lead to patients' highly variable treatment outcomes. Here, we have analysed the utility of the GAS5 tumour-suppressor lncRNA in improving BlCa prognosis. METHODS: GAS5 was quantified in a screening cohort of 176 patients. Hedegaard et al. (2016) (n = 476) and TCGA provisional (n = 413) were used as validation cohorts. Survival analysis was performed using recurrence and progression for NMIBC, or death for MIBC...
October 30, 2018: British Journal of Cancer
Erlin Sun, Kangkang Liu, Kun Zhao, Lining Wang
Tumor markers of bladder cancer (BC) have been investigated for many years, but the clinical treatment based on these biomarkers is still unsatisfactory. STK32C, a member of the serine/threonine protein kinase of AGC superfamily, was first found to be highly expressed in brain tissues; however, the role of STK32C in malignant disease has not been determined. Data from TCGA database showed that the STK32C gene is overexpressed in BC and a number of other human tumors. In the current study, immunohistochemistry revealed that high expression of STK32C protein in tumor tissues was significantly associated with poor clinico pathologic features and a short relapse-free survival (RFS) in patients with BC...
October 25, 2018: Cancer Biology & Therapy
Yue-Peng Cao, Jun Zhou, Wei-Jian Li, Yang Shao, Shu-Yun Zheng, Tian Tian, Kai-Peng Xie, Xiang Yan
BACKGROUND/AIMS: Bladder cancer (BC) is one of the most frequent urologic tumors worldwide. However, long non-coding RNA(lncRNA) expression profiles in BC progression remain unclear. This study aimed to explore lncRNA expression profiles in different grades of bladder cancer and normal urothelium tissues. METHODS: We performed high-throughput sequencing in BC tissues of different grade and obtained the expression profiles of its lncRNAs. Then, aberrantly expressed lncRNAs were validated by quantitative reverse transcription polymerase chain reaction (RT-PCR)...
2018: Cellular Physiology and Biochemistry
Wangjian Li, Lihong Ye, Yongliang Chen, Peng Chen
BACKGROUND: Genetic alterations play a significant role in the progression of bladder cancer. Identifying novel biomarkers to personalize the therapeutic regimen and evaluate the prognosis of patients with bladder cancer is vital. Prolyl 3-hydroxylase family member 4 (P3H4) is significantly involved in several types of human cancer. However, the effect of P3H4 in bladder cancer remains unknown. METHODS: The mRNA expression of P3H4 was measured in 44 paired tumors and adjacent normal tissues by using real-time reverse transcription-polymerase chain reaction...
October 15, 2018: World Journal of Surgical Oncology
Alice Yu, Jose Joao Mansure, Shraddha Solanki, D Robert Siemens, Madhuri Koti, Ana B T Dias, Miguel M Burnier, Fadi Brimo, Wassim Kassouf
Tumor-Infiltrating Lymphocytes (TILs) has been shown to be essential to predict disease outcome in several types of cancers. Moreover, the distribution of cytotoxic T lymphocytes (CD8+) and T cells in general (CD3+) have been used to establish an Immunoscore, as a new cancer prognosticator for survival in colon and lung cancer. In bladder cancer, immune activation has been shown to be associated with genomic subtypes of muscle invasive bladder cancer (MIBC). We sought to evaluate the prognostic impact of these immune cell types in MIBC patients treated with radical cystectomy...
2018: PloS One
Xin Chen, Rixin Chen, Wen-Su Wei, Yonghong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gangjun Yuan, Siliang Chen, Shen-Jie Guo, Kanghua Xiao, Zhuo-Wei Liu, Jun Hang Luo, Fang-Jian Zhou, Dan Xie
PURPOSE: Circular RNAs (circRNAs), a novel class of non-coding RNAs, have recently been drawn lots of attention in the pathogenesis of human cancers. However, the role of circRNAs in cancer cells epithelial-mesenchymal transition (EMT) remains unclear. In this study, we aimed to identify novel circRNAs that regulates urothelial carcinoma of the bladder (UCB) cells EMT and explored their regulatory mechanisms and clinical significance in UCBs. EXPERIMENTAL DESIGN: We first screened circRNA expression profiles using a circRNA microarray in paired UCB and normal tissues, and then studied the clinical significance of an up-regulated circRNA, circPRMT5, in a large cohort of UCB patients...
October 10, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Sining Zhu, Juan Jin, Samantha Gokhale, Angeli M Lu, Haiyan Shan, Jianjun Feng, Ping Xie
The tumor necrosis factor receptor (TNF-R)-associated factor (TRAF) family of cytoplasmic adaptor proteins regulate the signal transduction pathways of a variety of receptors, including the TNF-R superfamily, Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and cytokine receptors. TRAF-dependent signaling pathways participate in a diverse array of important cellular processes, including the survival, proliferation, differentiation, and activation of different cell types. Many of these TRAF-dependent signaling pathways have been implicated in cancer pathogenesis...
2018: Frontiers in Immunology
Tilman Todenhöfer, Roland Seiler, Craig Stewart, Igor Moskalev, Jian Gao, Simroop Ladhar, Alireza Kamyabi, Nader Al Nakouzi, Tetsutaro Hayashi, Stephen Choi, Yuzhuo Wang, Sebastian Frees, Mads Daugaard, Htoo Zarni Oo, Pascale Fisel, Matthias Schwab, Elke Schaeffeler, James Douglas, Jörg Hennenlotter, Jens Bedke, Ewan A Gibb, Ladan Fazli, Arnulf Stenzl, Peter C Black
INTRODUCTION & OBJECTIVES: The significance of lactate transporters has been recognized in various cancer types, but their role in urothelial carcinoma (UC) remains mostly unknown. The aim of the present study was to investigate the functional importance of the monocarboxylate transporter (MCT) 4 in preclinical models of UC and to assess its relevance in patient tumors. MATERIALS & METHODS: The association of MCT4 expression with molecular subtypes and outcome was determined in The Cancer Genome Atlas (TCGA) cohort and two independent cohorts of patients with UC...
September 27, 2018: Molecular Cancer Therapeutics
Qi Jiang, Qiang Fu, Yuan Chang, Zheng Liu, Junyu Zhang, Le Xu, Yu Zhu, Yiwei Wang, Weijuan Zhang, Jiejie Xu
PURPOSE: CD19+ tumor-infiltrating B-cells (CD19+ TIB) play a crucial role in tumorigenesis, but their clinical relevance in muscle-invasive bladder cancer (MIBC) remains unknown. This study aimed to investigate the prognostic value of CD19+ TIB for post-surgery survival and adjuvant chemotherapy response in MIBC. EXPERIMENTAL DESIGN: We assessed TIB by immunohistochemical staining of CD19 in 246 MIBC patients from Zhongshan Hospital and Shanghai Cancer Center. We evaluated the survival benefit of platinum-based chemotherapy according to CD19+ TIB...
September 26, 2018: Cancer Immunology, Immunotherapy: CII
Thomas S Worst, Cleo-Aron Weis, Robert Stöhr, Simone Bertz, Markus Eckstein, Wolfgang Otto, Johannes Breyer, Arndt Hartmann, Christian Bolenz, Ralph M Wirtz, Philipp Erben
Deletions of the cell cycle control gene CDKN2A are described as progression markers of non-muscle invasive bladder cancer and to be associated with fibroblast growth factor 3 (FGFR3) mutations. The prognostic role of CDKN2A RNA expression in muscle invasive bladder cancer (MIBC) is under discussion. In 80 MIBC patients (m/f 60/20) who underwent radical cystectomy the expression of CDKN2A and FGFR3 was examined with qRT-PCR (test cohort). The MDA cohort (n = 57) and the TCGA cohort (n = 365) served for validation...
September 26, 2018: Scientific Reports
Bin Jiang, Su Hailong, Jun Yuan, Hu Zhao, Wenkai Xia, Zhenlei Zha, Wu Bin, Zhili Liu
Bladder cancer is a common urological malignancies world-wide. Recently, a growing number of evidence have highlighted the importance of long noncoding RNAs (lncRNAs) in multiple cancers development and progression. However, the expression pattern of lncRNAs in bladder cancer and their underlying function remain poorly understood. To identify lncRNAs profile alterations and uncover valuable lncRNA candidates for bladder cancer diagnostic, we conducted a comprehensively lncRNAs profiling analyses and explored their clinical relevance using The Cancer Genome Atlas (TCGA) data and three independent microarray profiling data from the Gene Expression Omnibus (GEO)...
September 19, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Nicolas Jonckheere, Isabelle Van Seuningen
BACKGROUND: MUC4 is a membrane-bound mucin that promotes carcinogenetic progression and is often proposed as a promising biomarker for various carcinomas. In this manuscript, we analyzed large scale genomic datasets in order to evaluate MUC4 expression, identify genes that are correlated with MUC4 and propose new signatures as a prognostic marker of epithelial cancers. METHODS: Using cBioportal or SurvExpress tools, we studied MUC4 expression in large-scale genomic public datasets of human cancer (the cancer genome atlas, TCGA) and cancer cell line encyclopedia (CCLE)...
September 20, 2018: Journal of Translational Medicine
Chun-Peng Liu, Jian-Hua Zhang, Shuai-Chao Zheng, Jing Liu, Jin-Cheng Guo
A number of studies has shown that long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and protein coding genes (PCGs) are involved in various pathophysiological processes and can be used as prognostic biomarkers in cancer patients. The purpose of this study was to find a multidimensional transcriptome signature to predict clinical outcomes in bladder cancer. Using Cox's proportional hazards regression analysis and the random survival forest algorithm, we mined the expression profile data of 239 bladder cancer patients derived from The Cancer Genome Atlas (TCGA) public database...
November 2018: Oncology Reports
Hai-Feng Wang, Jian-Hui Wu, Jun-Wei Gai, Shi-Qiang Yang, Qing-Tong Ma, Hong-Shun Ma, Qiang Feng
Bladder cancer (BC) has been regarded as the most common malignancy of the urinary system worldwide. With lack of investigations for molecular pathogenesis underlying that develop BC, the therapeutic efficacy of several therapeutic approaches existing is still unsatisfactory. Here, our study aimed to explore the potentially biological function of MAN1B1 on BC. In this study, MAN1B1 expression level in BC tissues and normal tissues was analyzed based on The Cancer Genome Atlas (TCGA) data and correlation between its expression and prognosis was determined using Kaplan-Meier analysis...
December 30, 2018: Gene
Alejo Rodriguez-Vida, Seth P Lerner, Joaquim Bellmunt
Bladder cancer (BC) remains an aggressive disease with a poor prognosis, especially for patients with metastatic disease who have a limited median overall survival of 14 months. Urothelial carcinomas harbor frequent molecular dysregulations including recurrent mutations and copy number alteration, some of which could be potential therapeutic targets. However, no molecularly targeted agents have been approved to date for the treatment of advanced BC. Gaining new insights into the molecular landscape of BC will be critical to tailor future targeted agents for the treatment of advanced disease...
2018: Cancer Treatment and Research
Michael John Kerins, Aikseng Ooi
Identification and characterization of somatic mutations in cancer have important prognostication and treatment implications. Genes encoding the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription factor and its negative regulator, Kelch-like ECH-associated protein 1 (KEAP1), are frequently mutated in cancer. These mutations drive constitutive NRF2 activation and correlate with poor prognosis. Despite its apparent significance, a comprehensive catalogue of somatic NRF2 mutations across different tumor types is still lacking...
August 27, 2018: Scientific Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"